Which has higher earnings & valuation, HIMS or WGS?

Hims & Hers Health has higher revenue and earnings than GeneDx. Hims & Hers Health is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hims & Hers Health $2.37B 2.97 $128.37M -$0.09 N/A GeneDx $427.54M 4.67 -$21.02M -$2.68 N/A

Does the media prefer HIMS or WGS?

In the previous week, GeneDx had 21 more articles in the media than Hims & Hers Health. MarketBeat recorded 46 mentions for GeneDx and 25 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.22 beat GeneDx's score of 0.20 indicating that Hims & Hers Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 5 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral GeneDx 7 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, BLLN or WGS?

Billiontoone has higher earnings, but lower revenue than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Billiontoone $305.11M 20.70 $7.45M $0.55 249.69 GeneDx $427.54M 4.67 -$21.02M -$2.68 N/A

Does the media favor BLLN or WGS?

In the previous week, GeneDx had 41 more articles in the media than Billiontoone. MarketBeat recorded 46 mentions for GeneDx and 5 mentions for Billiontoone. Billiontoone's average media sentiment score of 0.41 beat GeneDx's score of 0.20 indicating that Billiontoone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Billiontoone 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GeneDx 7 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, SHC or WGS?

Sotera Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sotera Health $1.19B 4.33 $77.94M $0.41 44.01 GeneDx $427.54M 4.67 -$21.02M -$2.68 N/A

Is SHC or WGS more profitable?

Sotera Health has a net margin of 9.91% compared to GeneDx's net margin of -17.58%. Sotera Health's return on equity of 39.73% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 9.91% 39.73% 7.05% GeneDx -17.58% 9.15% 5.21%

Does the media refer more to SHC or WGS?

In the previous week, GeneDx had 36 more articles in the media than Sotera Health. MarketBeat recorded 46 mentions for GeneDx and 10 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.35 beat GeneDx's score of 0.20 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeneDx 7 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, WGS or RDNT?

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 4.67 -$21.02M -$2.68 N/A RadNet $2.04B 2.54 -$18.65M -$0.18 N/A

Is WGS or RDNT more profitable?

RadNet has a net margin of -0.66% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets GeneDx -17.58% 9.15% 5.21% RadNet -0.66% 2.77% 0.97%

Does the media prefer WGS or RDNT?

In the previous week, GeneDx had 41 more articles in the media than RadNet. MarketBeat recorded 46 mentions for GeneDx and 5 mentions for RadNet. RadNet's average media sentiment score of 0.42 beat GeneDx's score of 0.20 indicating that RadNet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 7 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral RadNet 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, VCYT or WGS?

Veracyte has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $561.90M 6.54 $66.35M $1.41 32.66 GeneDx $427.54M 4.67 -$21.02M -$2.68 N/A

Is VCYT or WGS more profitable?

Veracyte has a net margin of 20.37% compared to GeneDx's net margin of -17.58%. Veracyte's return on equity of 9.26% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 20.37% 9.26% 8.61% GeneDx -17.58% 9.15% 5.21%

Does the media favor VCYT or WGS?

In the previous week, GeneDx had 27 more articles in the media than Veracyte. MarketBeat recorded 46 mentions for GeneDx and 19 mentions for Veracyte. Veracyte's average media sentiment score of 0.63 beat GeneDx's score of 0.20 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 7 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive GeneDx 7 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Live Earnings Conference Call: GeneDx will host a live Q2 2026 earnings call on August 3, 2026 at 4:30PM ET. Get details.

GeneDx (WGS) Competitors

$67.05 +1.94 (+2.98%)

As of 11:40 AM Eastern

Compare

WGS vs. HIMS, BLLN, SHC, RDNT, and VCYT

Should you buy GeneDx stock or one of its competitors? MarketBeat compares GeneDx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GeneDx include Hims & Hers Health (HIMS), Billiontoone (BLLN), Sotera Health (SHC), RadNet (RDNT), and Veracyte (VCYT).

How does GeneDx compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and GeneDx (NASDAQ:WGS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Hims & Hers Health has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market. Comparatively, GeneDx has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Hims & Hers Health has higher revenue and earnings than GeneDx. Hims & Hers Health is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.37B	2.97	$128.37M	-$0.09	N/A
GeneDx	$427.54M	4.67	-$21.02M	-$2.68	N/A

63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by insiders. Comparatively, 25.2% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, GeneDx had 21 more articles in the media than Hims & Hers Health. MarketBeat recorded 46 mentions for GeneDx and 25 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.22 beat GeneDx's score of 0.20 indicating that Hims & Hers Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	5 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Neutral
GeneDx	7 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hims & Hers Health currently has a consensus price target of $31.43, suggesting a potential upside of 3.22%. GeneDx has a consensus price target of $87.43, suggesting a potential upside of 30.14%. Given GeneDx's stronger consensus rating and higher possible upside, analysts clearly believe GeneDx is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19
GeneDx	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Hims & Hers Health has a net margin of -0.56% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
GeneDx	-17.58%	9.15%	5.21%

Summary

GeneDx beats Hims & Hers Health on 9 of the 16 factors compared between the two stocks.

How does GeneDx compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and GeneDx (NASDAQ:WGS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

61.7% of GeneDx shares are held by institutional investors. 50.2% of Billiontoone shares are held by company insiders. Comparatively, 25.2% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Billiontoone has higher earnings, but lower revenue than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Billiontoone	$305.11M	20.70	$7.45M	$0.55	249.69
GeneDx	$427.54M	4.67	-$21.02M	-$2.68	N/A

In the previous week, GeneDx had 41 more articles in the media than Billiontoone. MarketBeat recorded 46 mentions for GeneDx and 5 mentions for Billiontoone. Billiontoone's average media sentiment score of 0.41 beat GeneDx's score of 0.20 indicating that Billiontoone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Billiontoone	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeneDx	7 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Billiontoone currently has a consensus price target of $126.00, indicating a potential downside of 8.25%. GeneDx has a consensus price target of $87.43, indicating a potential upside of 30.14%. Given GeneDx's stronger consensus rating and higher possible upside, analysts plainly believe GeneDx is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
GeneDx	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Billiontoone has a net margin of 0.00% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Billiontoone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Billiontoone	N/A	N/A	N/A
GeneDx	-17.58%	9.15%	5.21%

Summary

GeneDx beats Billiontoone on 8 of the 15 factors compared between the two stocks.

How does GeneDx compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and GeneDx (NASDAQ:WGS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Sotera Health has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, GeneDx has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

In the previous week, GeneDx had 36 more articles in the media than Sotera Health. MarketBeat recorded 46 mentions for GeneDx and 10 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.35 beat GeneDx's score of 0.20 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeneDx	7 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 15.4% of Sotera Health shares are held by company insiders. Comparatively, 25.2% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sotera Health has a net margin of 9.91% compared to GeneDx's net margin of -17.58%. Sotera Health's return on equity of 39.73% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	9.91%	39.73%	7.05%
GeneDx	-17.58%	9.15%	5.21%

Sotera Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.19B	4.33	$77.94M	$0.41	44.01
GeneDx	$427.54M	4.67	-$21.02M	-$2.68	N/A

Sotera Health currently has a consensus price target of $20.25, suggesting a potential upside of 12.22%. GeneDx has a consensus price target of $87.43, suggesting a potential upside of 30.14%. Given GeneDx's higher possible upside, analysts plainly believe GeneDx is more favorable than Sotera Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
GeneDx	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Sotera Health beats GeneDx on 11 of the 16 factors compared between the two stocks.

How does GeneDx compare to RadNet?

GeneDx (NASDAQ:WGS) and RadNet (NASDAQ:RDNT) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

GeneDx has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, RadNet has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

GeneDx presently has a consensus target price of $87.43, indicating a potential upside of 30.14%. RadNet has a consensus target price of $87.43, indicating a potential upside of 32.67%. Given RadNet's stronger consensus rating and higher possible upside, analysts plainly believe RadNet is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
RadNet	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.80

RadNet has a net margin of -0.66% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
RadNet	-0.66%	2.77%	0.97%

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	4.67	-$21.02M	-$2.68	N/A
RadNet	$2.04B	2.54	-$18.65M	-$0.18	N/A

61.7% of GeneDx shares are owned by institutional investors. Comparatively, 77.9% of RadNet shares are owned by institutional investors. 25.2% of GeneDx shares are owned by company insiders. Comparatively, 5.1% of RadNet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, GeneDx had 41 more articles in the media than RadNet. MarketBeat recorded 46 mentions for GeneDx and 5 mentions for RadNet. RadNet's average media sentiment score of 0.42 beat GeneDx's score of 0.20 indicating that RadNet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	7 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
RadNet	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RadNet beats GeneDx on 9 of the 17 factors compared between the two stocks.

How does GeneDx compare to Veracyte?

Veracyte (NASDAQ:VCYT) and GeneDx (NASDAQ:WGS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Veracyte has a net margin of 20.37% compared to GeneDx's net margin of -17.58%. Veracyte's return on equity of 9.26% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
GeneDx	-17.58%	9.15%	5.21%

Veracyte has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, GeneDx has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

61.7% of GeneDx shares are held by institutional investors. 1.6% of Veracyte shares are held by insiders. Comparatively, 25.2% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, GeneDx had 27 more articles in the media than Veracyte. MarketBeat recorded 46 mentions for GeneDx and 19 mentions for Veracyte. Veracyte's average media sentiment score of 0.63 beat GeneDx's score of 0.20 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	7 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
GeneDx	7 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veracyte has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$561.90M	6.54	$66.35M	$1.41	32.66
GeneDx	$427.54M	4.67	-$21.02M	-$2.68	N/A

Veracyte presently has a consensus target price of $56.13, suggesting a potential upside of 21.89%. GeneDx has a consensus target price of $87.43, suggesting a potential upside of 30.14%. Given GeneDx's stronger consensus rating and higher possible upside, analysts plainly believe GeneDx is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
GeneDx	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Veracyte beats GeneDx on 11 of the 17 factors compared between the two stocks.

Get GeneDx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WGS vs. The Competition

Export

Metric	GeneDx	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.00B	$9.92B	$6.79B	$12.63B
Dividend Yield	N/A	2.52%	2.59%	10.03%
P/E Ratio	-25.09	25.56	282.14	25.05
Price / Sales	4.67	5.48	573.43	80.07
Price / Cash	28.41	26.24	28.60	46.71
Price / Book	6.37	5.21	11.09	6.19
Net Income	-$21.02M	$311.05M	$3.49B	$347.61M
7 Day Performance	10.97%	-0.45%	0.42%	0.74%
1 Month Performance	-0.49%	-1.16%	-4.33%	-3.72%
1 Year Performance	-33.88%	26.54%	63.09%	20.27%

GeneDx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WGS GeneDx	4.1808 of 5 stars	$67.05 +3.0%	$87.43 +30.4%	-35.9%	$1.99B	$427.54M	N/A	1,300
HIMS Hims & Hers Health	2.4877 of 5 stars	$24.97 -14.8%	$31.43 +25.9%	-55.6%	$6.79B	$2.35B	N/A	2,442	Upcoming Earnings Gap Up High Trading Volume
BLLN Billiontoone	2.6308 of 5 stars	$132.52 -0.8%	$126.00 -4.9%	N/A	$6.15B	$354.54M	240.95	620
SHC Sotera Health	3.4653 of 5 stars	$17.53 -1.3%	$20.25 +15.5%	+60.2%	$5.06B	$1.16B	42.76	3,000	Positive News Upcoming Earnings
RDNT RadNet	3.3774 of 5 stars	$63.37 +0.2%	$87.43 +38.0%	+16.6%	$4.97B	$2.04B	N/A	11,264	Positive News Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WGS) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeneDx (WGS) Competitors

WGS vs. HIMS, BLLN, SHC, RDNT, and VCYT

How does GeneDx compare to Hims & Hers Health?

Summary

How does GeneDx compare to Billiontoone?

Summary

How does GeneDx compare to Sotera Health?

Summary

How does GeneDx compare to RadNet?

Summary

How does GeneDx compare to Veracyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WGS vs. The Competition

GeneDx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeneDx (WGS) Competitors

WGS vs. HIMS, BLLN, SHC, RDNT, and VCYT

How does GeneDx compare to Hims & Hers Health?

Which has more risk and volatility, HIMS or WGS?

Which has higher earnings & valuation, HIMS or WGS?

Do institutionals & insiders have more ownership in HIMS or WGS?

Does the media prefer HIMS or WGS?

Do analysts prefer HIMS or WGS?

Is HIMS or WGS more profitable?

Summary

How does GeneDx compare to Billiontoone?

Do insiders and institutionals hold more shares of BLLN or WGS?

Which has preferable valuation & earnings, BLLN or WGS?

Does the media favor BLLN or WGS?

Do analysts recommend BLLN or WGS?

Is BLLN or WGS more profitable?

Summary

How does GeneDx compare to Sotera Health?

Which has more volatility and risk, SHC or WGS?

Does the media refer more to SHC or WGS?

Do insiders & institutionals hold more shares of SHC or WGS?

Is SHC or WGS more profitable?

Which has higher valuation and earnings, SHC or WGS?

Do analysts rate SHC or WGS?

Summary

How does GeneDx compare to RadNet?

Which has more volatility & risk, WGS or RDNT?

Do analysts rate WGS or RDNT?

Is WGS or RDNT more profitable?

Which has stronger earnings and valuation, WGS or RDNT?

Do institutionals & insiders believe in WGS or RDNT?

Does the media prefer WGS or RDNT?

Summary

How does GeneDx compare to Veracyte?

Is VCYT or WGS more profitable?

Which has more risk and volatility, VCYT or WGS?

Do insiders & institutionals believe in VCYT or WGS?

Does the media favor VCYT or WGS?

Which has preferable valuation and earnings, VCYT or WGS?

Do analysts rate VCYT or WGS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WGS vs. The Competition

GeneDx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools